Aim Immunotech Inc (AIM)

$0.27 0.00 (N/A)
Market Cap 3.87M
Revenue (ttm) 90,000.00
Net Income (ttm) -13.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15,511.11%
Debt to Equity Ratio 0.10
Volume 585,900
Avg Vol 34,443,879
Day's Range N/A - N/A
Shares Out 14.56M
Stochastic %K 25%
Beta 1.20
Analysts Sell
Price Target $5.25

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon produ...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
Chessdoc
Chessdoc Jul. 15 at 11:37 AM
$AIM When are results known on the vote?
0 · Reply
fatpie68
fatpie68 Jul. 15 at 12:12 AM
On June 27th, $AIM had 27.72M OS with a 26.06M Float and Inside Ownership of 6.01%. Today it has 8.22M OS with a 7.68M Float and Inside Ownership of 72.25%. Can anyone tell me why Insiders bought up so many shares? I'm long and I like high Inside Ownership but the Short Float went from 12.30% up to 28.63% (source: FinViz) and that's a cause for concern.
1 · Reply
uuddlrlr
uuddlrlr Jul. 14 at 8:29 PM
$AIM Expectations - the special meeting will be underwhelming and provide no true value - all proposals will pass Hope to be wrong for both.
0 · Reply
TheLionofwallstreet
TheLionofwallstreet Jul. 14 at 7:39 PM
$AIM They are not in debt. Borrow money from lenders instead of screwing shareholders over and over again.
1 · Reply
jonjonson1234
jonjonson1234 Jul. 14 at 4:39 PM
$AIM When Equels took over the company in February 2016, the share price was $0.19 per share. If you owned 2 million shares then, your investment was worth $380,000.00 After the three reverse splits that have happened since then, you would now be left with 37 shares, currently worth $9.62 After the 1 for 25 reverse split, you would be left with one share worth about $6.25 and a check for about $3.37 for your fractional share. I think that it would be fair for that 2016 investor to wonder where his money went and to feel some regret for falling for the company's sales pitches in the first place.
2 · Reply
sschmid1
sschmid1 Jul. 14 at 4:10 PM
$AIM I’ve been thinking about the upcoming vote, and I think many people are looking at it from the wrong angle. The real question isn’t whether dilution is good. It isn’t. The real question is: What happens if AIM receives FDA alignment for a manageable Phase 3 later this year? A Phase 3 plan alone would be a major de-risking event and could move the stock significantly. But investors will immediately ask the next question: “How is AIM going to pay for it?” If the warrant proposals have been approved, AIM has a potential financing mechanism already in place. Those warrants are currently out of the money, so they’re not causing immediate dilution. They only become exercisable if the stock appreciates first—and if that happens, AIM could receive roughly $19M+ (plus another ~$3.7M from the already-approved Class G warrants if the stock reaches $1). That doesn’t eliminate financing risk, but it provides a credible path to raising a meaningful amount of capital.
1 · Reply
ultimatebastos
ultimatebastos Jul. 14 at 1:54 PM
$AIM https://www.yahoo.com/news/world/articles/majority-ebola-cases-unknown-chains-131230400.html
0 · Reply
ultimatebastos
ultimatebastos Jul. 14 at 11:58 AM
$AIM https://www.yahoo.com/news/world/articles/dr-congo-health-workers-ebola-114105907.html
0 · Reply
sschmid1
sschmid1 Jul. 14 at 11:58 AM
$AIM Calling me a “short” is actually pretty funny. I’ve been a long-term shareholder through years of dilution and reverse splits. If I were short, I’d probably be celebrating instead of trying to figure out which financing path gives existing shareholders the best chance from here. Nobody is asking anyone to ignore the last 10 years. My point is simply this: When you vote today, you’re not changing the past. You’re deciding what gives AIM the best chance of creating value from this point forward. If your answer is “vote no,” that’s perfectly valid. But then please explain how AIM should realistically finance a Phase 3 if FDA aligns on the trial design. That’s the discussion I’d like to have.
1 · Reply
Aimforsuccess
Aimforsuccess Jul. 14 at 11:39 AM
$AIM Did some Short actually say the vote should not be about the last 10 years? Just how stupid do they think stockholders are? Yeah, give management more money to lavish on themselves while diluting value. That is what some of us believe has been going on for 10 years in my opinion.
1 · Reply
Latest News on AIM
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

Jul 7, 2026, 9:03 AM EDT - 8 days ago

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

AIM ImmunoTech Proxy statement: Proxy filing

Jun 25, 2026, 8:00 AM EDT - 20 days ago

AIM ImmunoTech Proxy statement: Proxy filing

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

Jun 24, 2026, 8:29 AM EDT - 21 days ago

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences

Jun 23, 2026, 2:24 PM EDT - 21 days ago

AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

Jun 22, 2026, 8:45 AM EDT - 23 days ago

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

Jun 18, 2026, 9:01 AM EDT - 27 days ago

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

AIM ImmunoTech Registration statement: Registration filing

Jun 18, 2026, 8:00 AM EDT - 27 days ago

AIM ImmunoTech Registration statement: Registration filing

AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area

Jun 17, 2026, 4:15 AM EDT - 4 weeks ago

AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

Jun 15, 2026, 8:01 AM EDT - 4 weeks ago

AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency

AIM ImmunoTech Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 4 weeks ago

AIM ImmunoTech Proxy statement: Proxy filing

Infosys Collaborates with CMMI Institute to Shape Enterprise AI Maturity Framework; Achieves Milestone Recognition

Jun 11, 2026, 7:23 AM EDT - 4 weeks ago

Infosys Collaborates with CMMI Institute to Shape Enterprise AI Maturity Framework; Achieves Milestone Recognition

INFY

AIM ImmunoTech Inc trading resumes

2026-06-09T13:50:10.000Z - 5 weeks ago

AIM ImmunoTech Inc trading resumes

AIM ImmunoTech announces $2.65M registered direct offering

2026-06-09T13:41:34.000Z - 5 weeks ago

AIM ImmunoTech announces $2.65M registered direct offering

AIM ImmunoTech Inc trading halted, news pending

2026-06-09T13:29:35.000Z - 5 weeks ago

AIM ImmunoTech Inc trading halted, news pending

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

Jun 9, 2026, 9:29 AM EDT - 5 weeks ago

AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

AIM ImmunoTech registers to sell 31.29M shares of common stock for holders

2026-06-08T20:12:21.000Z - 5 weeks ago

AIM ImmunoTech registers to sell 31.29M shares of common stock for holders

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Jun 8, 2026, 8:33 AM EDT - 5 weeks ago

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Registration statement: Registration filing

Jun 8, 2026, 8:00 AM EDT - 5 weeks ago

AIM ImmunoTech Registration statement: Registration filing

AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness

Jun 4, 2026, 8:55 AM EDT - 5 weeks ago

AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness

3 Penny Stocks Drawing Market Attention, 6/2/26

2026-06-02T17:36:51.000Z - 6 weeks ago

3 Penny Stocks Drawing Market Attention, 6/2/26

ANY HKIT

AIM ImmunoTech enrolls final subject in pancreatic cancer development program

2026-06-01T13:52:59.000Z - 6 weeks ago

AIM ImmunoTech enrolls final subject in pancreatic cancer development program

AZN

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

Jun 1, 2026, 8:58 AM EDT - 6 weeks ago

AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

May 27, 2026, 8:47 AM EDT - 7 weeks ago

AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration

AIM ImmunoTech Inc trading resumes

2026-05-20T19:20:11.000Z - 7 weeks ago

AIM ImmunoTech Inc trading resumes

AIM ImmunoTech announces $2.4M registered direct offering

2026-05-20T19:10:27.000Z - 7 weeks ago

AIM ImmunoTech announces $2.4M registered direct offering

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

May 20, 2026, 3:02 PM EDT - 7 weeks ago

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

AIM ImmunoTech Inc trading halted, news pending

2026-05-20T19:00:12.000Z - 7 weeks ago

AIM ImmunoTech Inc trading halted, news pending

CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework

May 19, 2026, 11:41 AM EDT - 2 months ago

CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

May 19, 2026, 8:02 AM EDT - 2 months ago

AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities

AIM ImmunoTech Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

AIM ImmunoTech Quarterly report: Q1 2026

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

May 14, 2026, 8:41 AM EDT - 2 months ago

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

May 8, 2026, 8:40 AM EDT - 2 months ago

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

May 7, 2026, 8:23 AM EDT - 2 months ago

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

ORR

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Apr 16, 2026, 4:00 PM EDT - 3 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

AIM ImmunoTech highlights accelerating momentum in pancreatic cancer program

2026-04-16T13:59:51.000Z - 3 months ago

AIM ImmunoTech highlights accelerating momentum in pancreatic cancer program

AIM ImmunoTech Provides Routine Update on Annual Filings

Apr 13, 2026, 6:00 PM EDT - 3 months ago

AIM ImmunoTech Provides Routine Update on Annual Filings

AIM ImmunoTech Annual report: Q4 2025

Mar 27, 2026, 4:00 PM EDT - 3 months ago

AIM ImmunoTech Annual report: Q4 2025

Biotech Alert: Searches spiking for these stocks today

2026-03-20T14:55:28.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

Why Is AIM ImmunoTech Stock (AIM) Up Today?

2026-03-18T13:47:09.000Z - 4 months ago

Why Is AIM ImmunoTech Stock (AIM) Up Today?

AIM announces approval of patent for Ampligen in Japan

2026-03-18T12:51:46.000Z - 4 months ago

AIM announces approval of patent for Ampligen in Japan

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

Mar 18, 2026, 8:36 AM EDT - 4 months ago

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

AIM ImmunoTech Announces Closing of its Rights Offering

Mar 6, 2026, 7:00 PM EST - 4 months ago

AIM ImmunoTech Announces Closing of its Rights Offering

Biotech Alert: Searches spiking for these stocks today

2026-03-04T15:25:35.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

AIM ImmunoTech announces preliminary results of rights offering

2026-03-04T14:05:33.000Z - 4 months ago

AIM ImmunoTech announces preliminary results of rights offering

AIM ImmunoTech signs agreement for planning of Phase 3 trial of Ampligen

2026-03-02T14:10:12.000Z - 4 months ago

AIM ImmunoTech signs agreement for planning of Phase 3 trial of Ampligen

TMO

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

Mar 2, 2026, 9:00 AM EST - 4 months ago

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

AIM ImmunoTech reminds stockholders of expiration date for rights offering

2026-02-27T14:11:50.000Z - 4 months ago

AIM ImmunoTech reminds stockholders of expiration date for rights offering

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

Feb 27, 2026, 9:00 AM EST - 4 months ago

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

AIM ImmunoTech extends subscription period of rights offering

2026-02-25T14:19:06.000Z - 4 months ago

AIM ImmunoTech extends subscription period of rights offering

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

Feb 23, 2026, 8:55 AM EST - 5 months ago

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Feb 19, 2026, 4:00 PM EST - 5 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

Feb 12, 2026, 4:35 PM EST - 5 months ago

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 1:40 PM EST - 5 months ago

AIM ImmunoTech Transcript: Corporate Connect Webinar Series

AIM ImmunoTech Announces Commencement of Rights Offering

Feb 11, 2026, 8:30 AM EST - 5 months ago

AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech Registration statement: Registration Filing

Feb 10, 2026, 7:00 AM EST - 5 months ago

AIM ImmunoTech Registration statement: Registration Filing

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 6, 2026, 8:55 AM EST - 5 months ago

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Feb 5, 2026, 8:40 AM EST - 5 months ago

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

AIM ImmunoTech Registration statement: Registration Filing

Jan 29, 2026, 7:00 AM EST - 5 months ago

AIM ImmunoTech Registration statement: Registration Filing

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

Jan 23, 2026, 1:22 PM EST - 6 months ago

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

AIM ImmunoTech Registration statement: Registration filing

Jan 23, 2026, 7:00 AM EST - 6 months ago

AIM ImmunoTech Registration statement: Registration filing

AIM ImmunoTech Transcript: AGM 2025

Dec 16, 2025, 11:00 AM EST - 7 months ago

AIM ImmunoTech Transcript: AGM 2025

AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series

Dec 4, 2025, 4:00 PM EST - 7 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series

AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

Dec 1, 2025, 8:55 AM EST - 8 months ago

AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

Nov 18, 2025, 8:55 AM EST - 8 months ago

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

AIM ImmunoTech Quarterly report: Q3 2025

Nov 17, 2025, 4:00 PM EST - 8 months ago

AIM ImmunoTech Quarterly report: Q3 2025

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

Nov 10, 2025, 8:55 AM EST - 8 months ago

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Nov 4, 2025, 9:05 AM EST - 9 months ago

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

AIM ImmunoTech Proxy statement: Proxy Filing

Oct 29, 2025, 8:30 AM EDT - 9 months ago

AIM ImmunoTech Proxy statement: Proxy Filing

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Oct 20, 2025, 9:15 AM EDT - 9 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Sep 25, 2025, 8:45 AM EDT - 10 months ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Sep 4, 2025, 11:00 AM EDT - 11 months ago

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 21, 2025, 9:00 AM EDT - 11 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 9:00 AM EDT - 11 months ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

AIM ImmunoTech Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 11 months ago

AIM ImmunoTech Quarterly report: Q2 2025

AIM ImmunoTech Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 11 months ago

AIM ImmunoTech Earnings release: Q2 2025

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 8:55 AM EDT - 11 months ago

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

Aug 6, 2025, 9:00 AM EDT - 1 year ago

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Aug 4, 2025, 9:00 AM EDT - 1 year ago

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jul 2, 2025, 8:55 AM EDT - 1 year ago

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 20, 2025, 4:15 PM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 1 year ago

AIM ImmunoTech Resumes Trading on NYSE American

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 12, 2025, 8:00 AM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 1 year ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

AIM ImmunoTech Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

AIM ImmunoTech Quarterly report: Q1 2025

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

May 8, 2025, 8:45 AM EDT - 1 year ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Slides: Investor Presentation

Apr 8, 2025, 2:00 AM EDT - 1 year ago

AIM ImmunoTech Slides: Investor Presentation

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 7, 2025, 1:26 PM EDT - 1 year ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Chessdoc
Chessdoc Jul. 15 at 11:37 AM
$AIM When are results known on the vote?
0 · Reply
fatpie68
fatpie68 Jul. 15 at 12:12 AM
On June 27th, $AIM had 27.72M OS with a 26.06M Float and Inside Ownership of 6.01%. Today it has 8.22M OS with a 7.68M Float and Inside Ownership of 72.25%. Can anyone tell me why Insiders bought up so many shares? I'm long and I like high Inside Ownership but the Short Float went from 12.30% up to 28.63% (source: FinViz) and that's a cause for concern.
1 · Reply
uuddlrlr
uuddlrlr Jul. 14 at 8:29 PM
$AIM Expectations - the special meeting will be underwhelming and provide no true value - all proposals will pass Hope to be wrong for both.
0 · Reply
TheLionofwallstreet
TheLionofwallstreet Jul. 14 at 7:39 PM
$AIM They are not in debt. Borrow money from lenders instead of screwing shareholders over and over again.
1 · Reply
jonjonson1234
jonjonson1234 Jul. 14 at 4:39 PM
$AIM When Equels took over the company in February 2016, the share price was $0.19 per share. If you owned 2 million shares then, your investment was worth $380,000.00 After the three reverse splits that have happened since then, you would now be left with 37 shares, currently worth $9.62 After the 1 for 25 reverse split, you would be left with one share worth about $6.25 and a check for about $3.37 for your fractional share. I think that it would be fair for that 2016 investor to wonder where his money went and to feel some regret for falling for the company's sales pitches in the first place.
2 · Reply
sschmid1
sschmid1 Jul. 14 at 4:10 PM
$AIM I’ve been thinking about the upcoming vote, and I think many people are looking at it from the wrong angle. The real question isn’t whether dilution is good. It isn’t. The real question is: What happens if AIM receives FDA alignment for a manageable Phase 3 later this year? A Phase 3 plan alone would be a major de-risking event and could move the stock significantly. But investors will immediately ask the next question: “How is AIM going to pay for it?” If the warrant proposals have been approved, AIM has a potential financing mechanism already in place. Those warrants are currently out of the money, so they’re not causing immediate dilution. They only become exercisable if the stock appreciates first—and if that happens, AIM could receive roughly $19M+ (plus another ~$3.7M from the already-approved Class G warrants if the stock reaches $1). That doesn’t eliminate financing risk, but it provides a credible path to raising a meaningful amount of capital.
1 · Reply
ultimatebastos
ultimatebastos Jul. 14 at 1:54 PM
$AIM https://www.yahoo.com/news/world/articles/majority-ebola-cases-unknown-chains-131230400.html
0 · Reply
ultimatebastos
ultimatebastos Jul. 14 at 11:58 AM
$AIM https://www.yahoo.com/news/world/articles/dr-congo-health-workers-ebola-114105907.html
0 · Reply
sschmid1
sschmid1 Jul. 14 at 11:58 AM
$AIM Calling me a “short” is actually pretty funny. I’ve been a long-term shareholder through years of dilution and reverse splits. If I were short, I’d probably be celebrating instead of trying to figure out which financing path gives existing shareholders the best chance from here. Nobody is asking anyone to ignore the last 10 years. My point is simply this: When you vote today, you’re not changing the past. You’re deciding what gives AIM the best chance of creating value from this point forward. If your answer is “vote no,” that’s perfectly valid. But then please explain how AIM should realistically finance a Phase 3 if FDA aligns on the trial design. That’s the discussion I’d like to have.
1 · Reply
Aimforsuccess
Aimforsuccess Jul. 14 at 11:39 AM
$AIM Did some Short actually say the vote should not be about the last 10 years? Just how stupid do they think stockholders are? Yeah, give management more money to lavish on themselves while diluting value. That is what some of us believe has been going on for 10 years in my opinion.
1 · Reply
Marie52
Marie52 Jul. 14 at 11:35 AM
$AIM This will be a “long term forever” stock. Waiting forever for it to go up…
0 · Reply
ultimatebastos
ultimatebastos Jul. 14 at 10:29 AM
$AIM https://www.yahoo.com/news/world/articles/ebola-outbreak-least-double-formal-100646810.html
0 · Reply
sschmid1
sschmid1 Jul. 14 at 5:51 AM
$AIM Before deciding how to vote on the warrant proposals, I think these are the numbers shareholders should actually look at—not just the word “dilution.” Using the numbers from the proxy/filings: • Class H: 14.9M warrants @ $0.60 → $8.94M proceeds • Class I: 15.0M warrants @ $0.325 → $4.88M proceeds • Class J: 10.2M warrants @ $0.5189 → $5.29M proceeds Maximum potential proceeds for AIM: ~$19.1M. Maximum new shares issued if every warrant is exercised: 40.1M shares. Yes, that’s substantial potential dilution. But here’s the key point: At today’s share price (~$0.26), essentially none of these warrants are in the money. No one exercises an out-of-the-money warrant. So the dilution only occurs if the stock appreciates significantly first—and in that case AIM receives up to ~$19M of additional capital that could help finance a Phase 3 or strengthen its negotiating position. That’s why I view these warrants as contingent financing, not immediate dilution.
2 · Reply
sschmid1
sschmid1 Jul. 13 at 9:31 PM
$AIM I completely understand why many long-term shareholders are frustrated. Years of dilution and reverse splits have destroyed a lot of value, and nobody should pretend otherwise. But the upcoming vote shouldn’t be about the last 10 years. It should be about where AIM stands today. Many current shareholders—retail and institutional—entered after the recent financings at much lower prices than those of us who’ve been here for years. They’re down too, but their decision isn’t based on recovering losses from past dilution. It’s about maximizing value from this point forward. The real question isn’t “Did previous YES votes work out?” The real question is: Given today’s balance sheet, DURIPANC’s progress and a potential Phase 3 ahead, which financing path gives shareholders the best chance of creating value? Those are two very different questions.
1 · Reply
sschmid1
sschmid1 Jul. 13 at 9:18 PM
$AIM So let me get this straight… All DURIPANC interim results published over the past months and years have been positive — in fact, some have been extremely positive. And yet, according to this user, the next DURIPANC PR will somehow make financiers call Equels and hand him money for „free“. If positive clinical data alone immediately solved financing, delisting risk, attracted institutions and “washed out the shorts,” shouldn’t that have already happened? Apparently in this version of reality, partnership offers, government grants and free financing just appear on the CEO’s desk as soon as a good PR is issued. Unfortunately, biotech financing usually isn’t that simple.
1 · Reply
TheLionofwallstreet
TheLionofwallstreet Jul. 13 at 7:31 PM
$AIM Voted no. 80%+ shares are owned by retail. We should be able to shut this down. That being said. If they vote yes we are not totally screwed. Chances are against us but the rs does NOT have to be implemented. They can wait and use it as a backup if the stock falls below 10 cents and they need to regain compliance. Its a gamble both ways. They have 1 year to implement (if needed.) So... if moonshot news happens before that year they wont need to use it. I don't want the rs to happen at all route.
0 · Reply
PhantaJuicy
PhantaJuicy Jul. 13 at 5:38 PM
$AIM Under these circumstances, it is far better for shareholders to refuse the reverse split and the proposed warrants. Even if the company delists (as happened previously), the trials can still proceed, and Equels will be forced to find funding another way (through partnerships, licensing deals, government grants, and other normal means), which any competent CEO would have done already, instead of repeatedly destroying shareholder value. Any trial success will immediately raise the stock price and bring institutional investors. This would not only raise the stock price and mitigate delisting, without massive damage to shareholders, but would also wash out shorts and solve the longstanding problem of stock manipulation that has plagued this company for years and that Equels has never addressed. Trial success raises the price, solves delisting and washes out shorts and manipulation. Refusing the warrants and reverse split will simply force Equels to do his job for once.
1 · Reply
ultimatebastos
ultimatebastos Jul. 13 at 5:22 PM
$AIM one naked shorting piggy went to the market….
1 · Reply
Stocks_pumpr
Stocks_pumpr Jul. 13 at 2:35 PM
$AIM Tom must be fired.
1 · Reply
jonjonson1234
jonjonson1234 Jul. 13 at 1:01 PM
$AIM The insiders hold very few shares, and here will be the total number of shares after a 1-for-25 reverse split. Thomas K. Equels, CEO, 5,177 Peter W. Rodino III, COO 388 Robert Dickey IV, CFO 20 William M. Mitchell, M.D., Chairman of the Board of Directors 300 Nancy K. Bryan, Director 116 David Chemerow, Director 3,137 Ted D. Kellner, Director 1,489 Directors and executive officers as a group (7 persons) 10,260 (The notion of a CFO holding only 20 shares is pretty funny) (Here are the current, pre-reverse-split totals: Thomas K. Equels, CEO, 129,445 Peter W. Rodino III, COO 8,458 Robert Dickey IV, CFO 500 William M. Mitchell, M.D., Chairman of the Board of Directors 7,510 Nancy K. Bryan, Director 2,920 David Chemerow, Director 78,441 Ted D. Kellner, Director 37,240 Directors and executive officers as a group (7 persons) 264,514 )
1 · Reply
PhantaJuicy
PhantaJuicy Jul. 13 at 8:36 AM
$AIM So with a buyout price of $10 per share, our holder of 100,000 shares before the 100:1 split last year would have had $1,000,000. But after the split, the same shareholder would have only 1000 shares, and the same buyout at $10 would yield only $10,000. And after the upcoming 25:1 split, it will only yield $400. This is what Equels is doing to your investment. 100,000 shares became 1000 shares (after the 100:1 split) and then (after the 25:1 split) only 40 shares. This is what Equels accomplished in little more than one year. This is what Equels is doing to your investment.
1 · Reply
PhantaJuicy
PhantaJuicy Jul. 13 at 8:24 AM
$AIM A shareholder who bought 100,000 shares before the 2025 reverse split had only 1000 shares after the split, now worth only $250. Before the 2025 split, AIM had approximately 65,500,000 shares outstanding. After the split, there were 655,000 shares. This means your share count diminished but your proportion of total shares was still the same. But that didn’t last. Now — one year later — dilution led to 27,724,000 million current shares, with additional warrants proposed for 40,800,000 shares, for a total of 68,524,000 total shares. A massive loss from the reverse split followed by massive dilution causing further loss. No benefit whatsoever. Now Equels faces the same crisis — Delisting! Delisting! We need capital! — and wants to do it again. Equels gets a huge undeserved salary and 3% of any buyout. Shareholders get another massive loss.
0 · Reply